Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2024.11.004 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Julian Hamfjord und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospita…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carcinoembryonic Antigen, Circulating Tumor DNA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Cancer Society, Novo Nordisk Foundation, Region Midtjyllands Sundhedsvidenskabelige Forskningsfond.
Abstract (Originalsprache)
INTRODUCTION: Patients with metastatic colorectal cancer (mCRC) respond differently to first-line chemotherapy. Early identification of patients with limited or no clinical benefit could prompt a timelier introduction of second-line therapy and potentially lead to improved overall outcomes. Carcinoembryonic antigen (CEA) is currently the only blood-based marker in clinical use for disease control monitoring in mCRC. Circulating cell-free DNA (cfDNA), including circulating tumor DNA (ctDNA) could become a useful surrogate for oncological outcomes. MATERIALS AND METHODS: Forty patients with RAS-/BRAF-mutated mCRC from the prospective NORDIC-VII trial (NCT00145314) were included. An exploratory model system was made to describe the early on-treatment kinetics of CEA, cfDNA and ctDNA during first-line oxaliplatin-based chemotherapy, and investigate the associations with radiological response, progression-free survival (PFS) and overall survival (OS). RESULTS: Summary metrics were made, representing percentage change from treatment start to time-grid day 7 (P7), day 14 (P14), and day 49 (P49); slope from time-grid day 0 to 7 (S7), day 8 to 14 (S14), and day 15 to 49 (S49); and area under the curve from time-grid day 0 to 49 (AUC). Notably P49 and S49 for ctDNA and CEA were associated with radiological response and/or PFS. The early dynamics of the two markers differed substantially, with faster and more marked changes in ctDNA compared with CEA. Nine patients did not reach complete/near complete molecular ctDNA response close to first evaluation (∼week 8), a state associated with a short PFS (HR 2.72; 95% CI, 1.22-6.06; P = .01) and OS (HR 3.12; 95% CI, 1.35-7.23; P < .01). Contrary, twenty-two patients did not reach radiological response (i.e., complete or partial response) at first evaluation, but this was not associated with PFS (HR 1.21; 95% CI, 0.64-2.30; P = .55) nor OS (HR 1.37; 95% CI, 0.70-2.68; P = .37). CONCLUSION: Early dynamics of ctDNA during first-line oxaliplatin-based chemotherapy hold prognostic value, supporting the idea of prospectively validating a ctDNA-RECIST framework in the early care pathway of mCRC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00145314.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine,…
- Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: uxtour@ous-hf.no.
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
- Department of Oncology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Oncology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
Förderung
- Swedish Cancer Society
- Novo Nordisk Foundation
- Region Midtjyllands Sundhedsvidenskabelige Forskningsfond
- Sanofi
- The Norwegian Cancer Society
- Merck KGaA
Zitieren
APA
Hamfjord, J., Guren, T. K., Glimelius, B., Sorbye, H., Pfeiffer, P., Dajani, O., Lingjærde, O. C., Tveit, K. M., Spindler, K. G., Pallisgaard, N., & Kure, E. H. (2025). Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.11.004
Vancouver
Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, et al. Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.11.004
BibTeX
@article{Hamfjord2025,
author = {Hamfjord, Julian and Guren, Tormod Kyrre and Glimelius, Bengt and Sorbye, Halfdan and Pfeiffer, Per and Dajani, Olav and Lingjærde, Ole Christian and Tveit, Kjell Magne and Spindler, Karen-Lise Garm and Pallisgaard, Niels and Kure, Elin H},
title = {Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2024.11.004}
}
EUVIMED